Metabolomic profiling of the autosomal dominant polycystic kidney disease rat model

Clinical and Experimental Nephrology

Volumn 15, Issue 5, 2011, Pages 676-687

  Toyohara, Takafumi ^a   Suzuki, Takehiro ^a   Akiyama, Yasutoshi ^a   Yoshihara, Daisuke ^b   Takeuchi, Yoichi ^a   Mishima, Eikan ^a   Kikuchi, Koichi ^a   Suzuki, Chitose ^a   Tanemoto, Masayuki ^a   Ito, Sadayoshi ^a   Nagao, Shizuko ^b   Soga, Tomoyoshi ^c   Abe, Takaaki ^a,d  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

ADPKD; Biomarker; CE MS; Uremic toxin

Indexed keywords

10 HYDROXYDECANOATE; 5 METHYLDEOXYCYTIDINE; ALLANTOATE; ALPHA HYDROXYBENZOATE; ANION; BIOLOGICAL MARKER; CATION; DECANOIC ACID; DEOXYCYTIDINE; ECTOINE; GLUCOSAMINE; HYDROCINNAMIC ACID; PHENACETURATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLOOD ANALYSIS; CAPILLARY ELECTROPHORESIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HETEROZYGOSITY; HUMAN VERSUS ANIMAL COMPARISON; KIDNEY INJURY; KIDNEY POLYCYSTIC DISEASE; MALE; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; RAT;

ACONITIC ACID; ANIMALS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, CAPILLARY; HIPPURATES; HUMANS; INDICAN; MALE; MASS SPECTROMETRY; METABOLOMICS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RATS; RENAL INSUFFICIENCY;

EID: 80755140060     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0467-4     Document Type: Article

References (45)

1. CG Iglesias VE Torres KP Offord KE Holley CM Beard LT Kurland 1983 Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980 Am J Kidney Dis 2 630 639 6846334 1:STN:280:DyaL3s3gtFaisA%3D%3D (Pubitemid 13078640)
2. RW Schrier 2006 Optimal care of autosomal dominant polycystic kidney disease patients Nephrology (Carlton) 11 124 130 10.1111/j.1440-1797.2006.00535. x 1:CAS:528:DC%2BD28Xlt1Khu7c%3D
3. R Vanholder S Van Laecke G Glorieux 2008 What is new in uremic toxicity? Pediatr Nephrol 23 1211 1221 18324423 10.1007/s00467-008-0762-9
4. B Marescau G Nagels I Possemiers ME De Broe I Becaus JM Billiouw W Lornoy PP De Deyn 1997 Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency Metabolism 46 1024 1031 9284891 10.1016/S0026-0495(97)90273-0 1:CAS:528:DyaK2sXlslSjt7g%3D (Pubitemid 27371819)
5. JT Kielstein C Zoccali 2008 Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease Curr Opin Nephrol Hypertens 17 609 615 18941355 10.1097/MNH.0b013e328314b6ca 1:CAS:528:DC%2BD1cXht1KmurnO
6. R Vanholder R De Smet G Glorieux A Argiles U Baurmeister P Brunet W Clark G Cohen PP De Deyn R Deppisch B Descamps-Latscha T Henle A Jorres HD Lemke ZA Massy J Passlick-Deetjen M Rodriguez B Stegmayr P Stenvinkel C Tetta C Wanner W Zidek 2003 Review on uremic toxins: classification, concentration, and interindividual variability Kidney Int 63 1934 1943 12675874 10.1046/j.1523-1755.2003.00924.x 1:CAS:528:DC%2BD3sXjslygsbk%3D (Pubitemid 36513344)
7. A Torremans B Marescau B Kranzlin N Gretz JM Billiouw R Vanholder R De Smet K Bouwman R Brouns PP De Deyn 2006 Biochemical validation of a rat model for polycystic kidney disease: comparison of guanidino compound profile with the human condition Kidney Int 69 2003 2012 16641922 10.1038/sj.ki.5000443 1:CAS:528:DC%2BD28XkvVyrtr4%3D (Pubitemid 43924264)
8. T Toyohara T Suzuki R Morimoto Y Akiyama T Souma HO Shiwaku Y Takeuchi E Mishima M Abe M Tanemoto S Masuda H Kawano K Maemura M Nakayama H Sato T Mikkaichi H Yamaguchi S Fukui Y Fukumoto H Shimokawa K Inui T Terasaki J Goto S Ito T Hishinuma I Rubera M Tauc Y Fujii-Kuriyama H Yabuuchi Y Moriyama T Soga T Abe 2009 Slco4c1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation J Am Soc Nephrol 20 2546 2555 19875811 10.1681/ASN.2009070696 1:CAS:528:DC%2BD1MXhs1WitbzE
9. T Toyohara Y Akiyama T Suzuki Y Takeuchi E Mishima M Tanemoto A Momose N Toki H Sato M Nakayama A Hozawa I Tsuji S Ito T Soga T Abe 2010 Metabolomic profiling of uremic solutes in CKD patients Hypertens Res 33 944 952 20613759 10.1038/hr.2010.113
10. T Soga Y Ueno H Naraoka Y Ohashi M Tomita T Nishioka 2002 Simultaneous determination of anionic intermediates for Bacillus subtilis metabolic pathways by capillary electrophoresis electrospray ionization mass spectrometry Anal Chem 74 2233 2239 12038746 10.1021/ac020064n 1:CAS:528:DC%2BD38XivVOitbY%3D (Pubitemid 34526027)
11. T Mikkaichi T Suzuki T Onogawa M Tanemoto H Mizutamari M Okada T Chaki S Masuda T Tokui N Eto M Abe F Satoh M Unno T Hishinuma K Inui S Ito J Goto T Abe 2004 Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney Proc Natl Acad Sci USA 101 3569 3574 14993604 10.1073/pnas.0304987101 1:CAS:528:DC%2BD2cXisFWmtrY%3D (Pubitemid 38338236)
12. K Schafer N Gretz M Bader I Oberbaumer KU Eckardt W Kriz S Bachmann 1994 Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease Kidney Int 46 134 152 7933831 10.1038/ki.1994.253 1:STN:280: DyaK2M%2FhvFChuw%3D%3D (Pubitemid 24210445)
13. S Nagao T Ushijima M Kasahara T Yamaguchi M Kusaka J Matsuda M Nagao H Takahashi 1999 Closely linked polymorphic markers for determining the autosomal dominant allele (cy) in rat polycystic kidney disease Biochem Genet 37 227 235 10624513 10.1023/A:1018742807031 1:CAS:528:DyaK1MXntFCltbk%3D (Pubitemid 29530089)
14. T Soga Y Ohashi Y Ueno H Naraoka M Tomita T Nishioka 2003 Quantitative metabolome analysis using capillary electrophoresis mass spectrometry J Proteome Res 2 488 494 14582645 10.1021/pr034020m 1:CAS:528:DC%2BD3sXkvFWltrc%3D (Pubitemid 37376843)
15. T Soga DN Heiger 2000 Amino acid analysis by capillary electrophoresis electrospray ionization mass spectrometry Anal Chem 72 1236 1241 10740865 10.1021/ac990976y 1:CAS:528:DC%2BD3cXhtFCksro%3D (Pubitemid 30163781)
16. T Soga K Igarashi C Ito K Mizobuchi HP Zimmermann M Tomita 2009 Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry Anal Chem 81 15 6165 6174 19522513 10.1021/ac900675k 1:CAS:528:DC%2BD1MXnt1Wru7w%3D
17. O Levillain B Marescau PP de Deyn 1995 Guanidino compound metabolism in rats subjected to 20% to 90% nephrectomy Kidney Int 47 464 472 7536856 10.1038/ki.1995.59 1:CAS:528:DyaK2MXkvVWgs7o%3D
18. D Pawlak K Pawlak J Malyszko M Mysliwiec W Buczko 2001 Accumulation of toxic products degradation of kynurenine in hemodialyzed patients Int Urol Nephrol 33 399 404 12092667 10.1023/A:1015238418500 1:STN:280: DC%2BD38zkvFyksA%3D%3D (Pubitemid 34575400)
19. D Pawlak A Tankiewicz W Buczko 2001 Kynurenine and its metabolites in the rat with experimental renal insufficiency J Physiol Pharmacol 52 755 766 11785771 1:CAS:528:DC%2BD38XlvVGisw%3D%3D (Pubitemid 34042360)
20. ME Swendseid M Wang I Vyhmeister W Chan F Siassi CF Tam JD Kopple 1975 Amino acid metabolism in the chronically uremic rat Clin Nephrol 3 240 246 237643 1:CAS:528:DyaE28XktlWgt74%3D
21. I Ceballos P Chauveau V Guerin J Bardet P Parvy P Kamoun P Jungers 1990 Early alterations of plasma free amino acids in chronic renal failure Clin Chim Acta 188 101 108 2379310 10.1016/0009-8981(90)90154-K 1:STN:280: DyaK3czjs1Wjsw%3D%3D (Pubitemid 20150115)
22. R Amathieu S Racine M Triba MP Poloujadoff SW Borron N Bouchemal F Lapostolle M Merouani L Le Moyec F Adnet 2007 Use of nuclear magnetic resonance spectroscopy to assess renal dysfunction after hypertonic-hyperoncotic resuscitation in rats J Trauma 63 379 387 17693840 10.1097/01.ta.0000240459. 95717.c0 (Pubitemid 47254651)
23. MA Bain R Faull G Fornasini RW Milne AM Evans 2006 Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis Nephrol Dial Transplant 21 1300 1304 16401621 10.1093/ndt/gfk056 1:CAS:528:DC%2BD28XjslKqsro%3D
24. T Shimizu M Fukagawa T Kuroda S Hata Y Iwasaki M Nemoto K Shirai S Yamauchi SB Margolin F Shimizu K Kurokawa 1997 Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy Kidney Int Suppl 63 S239 S243 9407470 1:CAS:528:DyaK2sXotVKgur4%3D
25. W Hart SA Duursma WJ Visser LK Njio 1975 The hydroxyproline content of plasma of patients with impaired renal function Clin Nephrol 4 104 108 1183097 1:STN:280:DyaE28%2Fkt1Kgsg%3D%3D
26. DO McGregor WJ Dellow M Lever PM George RA Robson ST Chambers 2001 Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations Kidney Int 59 2267 2272 11380830 1:CAS:528:DC%2BD3MXks1Klurw%3D (Pubitemid 32467620)
27. AM Evans RJ Faull RL Nation S Prasad T Elias SE Reuter G Fornasini 2004 Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease Kidney Int 66 1527 1534 15458447 10.1111/j.1523-1755.2004.00916.x 1:CAS:528:DC%2BD2cXpsVShu7g%3D (Pubitemid 39298386)
28. T Deguchi M Takemoto N Uehara WE Lindup A Suenaga M Otagiri 2005 Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats J Pharmacol Exp Ther 314 932 938 15879000 10.1124/jpet.105.085613 1:CAS:528:DC%2BD2MXntVSitrs%3D (Pubitemid 41043880)
29. PC Farrell FA Gotch JH Peters BJ Berridge Jr M Lam 1978 Binding of hippurate in normal plasma and in uremic plasma pre- and postdialysis Nephron 20 40 46 619299 10.1159/000181194 1:STN:280:DyaE1c%2FntF2ntw%3D%3D (Pubitemid 8217070)
30. T Niwa M Ise 1994 Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis J Lab Clin Med 124 96 104 8035108 1:CAS:528:DyaK2cXlslKrs7k%3D (Pubitemid 2125685)
31. VA DeBari O Frank H Baker MA Needle 1984 Water soluble vitamins in granulocytes, erythrocytes, and plasma obtained from chronic hemodialysis patients Am J Clin Nutr 39 410 415 6695840 1:STN:280:DyaL2c7isFWksA%3D%3D (Pubitemid 14154626)
32. SH Lee I Kim BC Chung 2007 Increased urinary level of oxidized nucleosides in patients with mild-to-moderate Alzheimer's disease Clin Biochem 40 936 938 17692303 10.1016/j.clinbiochem.2007.06.012 1:CAS:528: DC%2BD2sXpsFGrt78%3D (Pubitemid 47385812)
33. BF Becker 1993 Towards the physiological function of uric acid Free Radic Biol Med 14 615 631 8325534 10.1016/0891-5849(93)90143-I 1:CAS:528: DyaK3sXlslOqu7k%3D (Pubitemid 23172569)
34. SY Hwang JH Shin JS Hwang SY Kim JA Shin ES Oh S Oh JB Kim JK Lee IO Han 2010 Glucosamine exerts a neuroprotective effect via suppression of inflammation in rat brain ischemia/reperfusion injury Glia 58 1881 1892 20737476 10.1002/glia.21058
35. MF Roberts 2005 Organic compatible solutes of halotolerant and halophilic microorganisms Saline Syst 1 5 16176595 10.1186/1746-1448-1-5
36. V Cachofeiro M Goicochea SG de Vinuesa P Oubina V Lahera J Luno 2008 Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease Kidney Int Suppl 74 S4 S9 10.1038/ki.2008.516
37. R D'Hooge A Raes P Lebrun M Diltoer PP Van Bogaert J Manil F Colin PP De Deyn 1996 N-methyl-d-aspartate receptor activation by guanidinosuccinate but not by methylguanidine: behavioural and electrophysiological evidence Neuropharmacology 35 433 440 8793905 10.1016/0028-3908(96)00011-1 (Pubitemid 26189387)
38. R Vanholder R De Smet 1999 Pathophysiologic effects of uremic retention solutes J Am Soc Nephrol 10 1815 1823 10446951 1:CAS:528:DyaK1MXlt1Wqtr8%3D (Pubitemid 29364682)
39. C Zoccali FA Benedetto R Maas F Mallamaci G Tripepi LS Malatino R Boger 2002 Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease J Am Soc Nephrol 13 490 496 11805179 10.1097/01.ASN.0000032548.18973.0F 1:CAS:528:DC%2BD38XhtlWisr4%3D (Pubitemid 34106292)
40. D Fliser F Kronenberg JT Kielstein C Morath SM Bode-Boger H Haller E Ritz 2005 Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study J Am Soc Nephrol 16 2456 2461 15930091 10.1681/ASN.2005020179 1:CAS:528:DC%2BD2MXovVOku7Y%3D (Pubitemid 41725064)
41. D Wang S Strandgaard ML Borresen Z Luo SG Connors Q Yan CS Wilcox 2008 Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease Am J Kidney Dis 51 184 191 18215696 10.1053/j.ajkd.2007.09.020 1:CAS:528:DC%2BD1cXisVOlsb4%3D
42. I Zafar Y Tao S Falk K McFann RW Schrier CL Edelstein 2007 Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model Am J Physiol Renal Physiol 293 F854 F859 17581927 10.1152/ajprenal.00059.2007 1:CAS:528:DC%2BD2sXhtVOqt7nI (Pubitemid 47403356)
43. RW Schrier 2009 Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease J Am Soc Nephrol 20 1888 1893 19696226 10.1681/ASN.2008080882
44. V Patel R Chowdhury P Igarashi 2009 Advances in the pathogenesis and treatment of polycystic kidney disease Curr Opin Nephrol Hypertens 18 99 106 19430332 10.1097/MNH.0b013e3283262ab0 1:CAS:528:DC%2BD1MXltVWrsbY%3D
45. RD Gile BD Cowley Jr VH Gattone 2nd MP O'Donnell SK Swan JJ Grantham 1995 Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat Am J Kidney Dis 26 501 507 7645559 10.1016/0272-6386(95)90497-2 1:CAS:528:DyaK2MXoslaqsbo%3D